Table S1.
Questions on PSA testing V by general practitioners and urologists, n (%)
| Question | GPs | Urologists | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Never | Rarely | Sometimes | Often | Always | Never | Rarely | Sometimes | Often | Always | ||
| On which occasions do you inform your patient on PSA testing? | Within an early cancer detection examination | 7.3 (3) | 7.3 (3) | 9.8 (4) | 19.5 (8) | 56.1 (23) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 13 (92.9) |
| In case of a positive family anamnesis | 4 (9.8) | 2 (4.9) | 4 (9.8) | 9 (22.0) | 22 (53.7) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 0 (0.0) | 13 (92.9) | |
| In case of discomfort in the lower urinary tract | 7 (17.1) | 9 (22.0) | 8 (19.5) | 8 (19.5) | 9 (22.0) | 0 (0.0) | 1 (7.1) | 2 (14.3) | 8 (57.1) | 3 (21.4) | |
| In case of unclear discomfort | 5 (12.2) | 12 (29.3) | 10 (24.4) | 10 (24.4) | 4 (9.8) | 0 (0.0) | 1 (7.1) | 3 (21.4) | 7 (50.0) | 3 (21.4) | |
| How often do you discuss the following aspects with your patients before performing a PSA test? | Impact on overall mortality | 7 (17.1) | 7 (17.1) | 4 (9.8) | 9 (22.0) | 14 (34.1) | 1 (7.1) | 1 (7.1) | 3 (21.4) | 5 (35.6) | 4 (28.6) |
| Impact on disease-specific mortality | 3 (7.3) | 4 (9.8) | 3 (7.3) | 14 (34.1) | 17 (41.5) | 1 (7.1) | 1 (7.1) | 1 (7.1) | 6 (42.9) | 5 (35.7) | |
| Impact on risk of metastasis | 5 (12.2) | 4 (9.8) | 8 (19.5) | 9 (22.0) | 15 (36.6) | 0 (0.0) | 1 (7.1) | 1 (7.1) | 9 (64.3) | 3 (21.4) | |
| Potential overdiagnosis | 1 (2.4) | 2 (4.9) | 5 (12.2) | 10 (24.4) | 23 (56.1) | 1 (7.1) | 1 (7.1) | 1 (7.1) | 5 (35.7) | 6 (42.9) | |
| Issue of false positives | 0 (0.0) | 0 (0.0) | 6 (14.6) | 12 (29.3) | 23 (56.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (28.6) | 10 (71.4) | |
| Potential anxiety during waiting on test result | 6 (14.6) | 7 (17.1) | 6 (14.6) | 7 (17.1) | 15 (36.6) | 2 (14.3) | 4 (28.6) | 1 (7.1) | 6 (42.9) | 1 (7.1) | |
| Potential follow-up examinations if the test result is conspicuous | 1 (2.4) | 0 (0.0) | 8 (19.5) | 11 (26.8) | 21 (51.2) | 0 (0.0) | 0 (0.0) | 1 (7.1) | 3 (21.4) | 10 (71.4) | |
| Adverse effects of the treatment | 1 (2.4) | 4 (9.8) | 12 (29.3) | 11 (26.8) | 13 (31.7) | 0.0 (0) | 0.0 (0) | 6 (42.9) | 5 (35.7) | 3 (21.4) | |
Abbreviations: GPs, general practitioners; PSA, prostate-specific antigen.